Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Soligenix Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SNGX
Nasdaq
2834
https://www.soligenix.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Soligenix Inc
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
- May 16th, 2024 11:30 am
SNGX: Second Confirmatory Phase 3 Trial of HyBryte™ in CTCL to Initiate Before End of 2024…
- May 14th, 2024 2:12 pm
Soligenix First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- May 13th, 2024 11:28 am
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
- May 10th, 2024 11:30 am
Soligenix to Present at Upcoming Conferences
- May 6th, 2024 11:30 am
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
- Apr 25th, 2024 11:30 am
Soligenix Announces Pricing of $4.75 Million Public Offering
- Apr 18th, 2024 12:30 pm
Why Is Penny Stock Soligenix Trading Higher On Monday?
- Apr 15th, 2024 7:55 pm
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
- Apr 15th, 2024 11:30 am
SNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™…
- Apr 11th, 2024 3:16 pm
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
- Apr 11th, 2024 11:30 am
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
- Apr 3rd, 2024 11:30 am
SNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…
- Mar 20th, 2024 10:35 am
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
- Mar 15th, 2024 11:30 am
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
- Feb 8th, 2024 12:30 pm
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- Jan 26th, 2024 2:00 pm
Soligenix to Present at The Microcap Conference
- Jan 25th, 2024 12:30 pm
SNGX: Phase 2a Psoriasis Trial Achieves Clinical Success…
- Jan 10th, 2024 10:24 am
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
- Jan 8th, 2024 12:30 pm
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
- Jan 4th, 2024 12:30 pm
Scroll